Search
Displaying 751–760 of 1066 results
-
National Science Update - May 29, 2019
A deep dive into the research and clinical trial results that impact the inherited retinal disease community.
-
FDA Wins Case against Stem-Cell Clinic that Blinded Patients with Bogus Treatment
Research NewsA federal court ruled that the FDA has regulatory authority over these stem-cell procedures and the power to halt them.
-
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
Foundation NewsA discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.
-
Original Foundation Advocate Gertrude Weiss Celebrates 100th Birthday
Beacon StoriesGertrude Weiss was one of the early Foundation Fighting Blindness investors and advocates. Diagnosed with retinitis pigmentosa, Gertrude continues to live her life to the fullest. As a longtime friend, the Foundation honored Gertrude on her 100th birthday recently.
-
Information for affected individuals and their families about the role of genetic counseling.
-
Dr. Don Zack Honored for Research Contributions by ARVO and the Foundation Fighting Blindness
Research NewsDr. Zack is a member of the Foundation’s Scientific Advisory Board and chairs its Cellular Molecular Mechanisms of Disease study section.
-
Research News
Eye Bonds provide the opportunity to advance, and accelerate development for, more promising treatments into and through clinical trials and out to the people who need them.
-
Foundation Fighting Blindness Endorses 'Eye Bonds' Legislation
Foundation NewsBipartisan Bill Will Stimulate Up to $1 Billion in New Funding for Blindness Research
-
Access to Retinal Disease Eye Tissue
For over 25 years the Foundation Fighting Blindness has supported the collection of eye globes from donors diagnosed with an inherited retinal degeneration, which is housed at the Cleveland Clinic Cole Eye Institute. The collection of over 900 eye globes are freely available for retina research.
-
ARVO 2019: Gene Therapy Clinical Trial for RP Caused by RLBP1 Mutations Ongoing in Sweden
Research NewsIn a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
